Moatar, Alexandra Ioana, Chis, Aimee Rodica, Romanescu, Mirabela et al. · Scientific reports · 2023 · DOI
Researchers studied a tiny molecule in the blood called miR-195 in COVID-19 patients to see if it could predict who would get sicker. They found that miR-195 levels measured in the first two days after hospital admission were very good at telling the difference between patients with mild and severe COVID-19. Interestingly, their analysis suggests this molecule may affect how heart cells produce energy, which could be relevant to long COVID and chronic fatigue syndrome.
This study is relevant to ME/CFS because it identifies a biomarker associated with viral infection severity that may specifically affect mitochondrial function in the heart—a mechanism implicated in both post-COVID syndrome and ME/CFS. Understanding how acute viral infections trigger mitochondrial dysfunction could illuminate why some patients develop persistent fatigue and exercise intolerance after COVID-19, potentially opening new avenues for prediction and treatment of these conditions.
This study does not establish that miR-195 directly causes mitochondrial dysfunction or ME/CFS; it only correlates with COVID-19 severity and computationally predicts effects on mitochondrial pathways. It does not prove that long COVID or ME/CFS develop through the same miR-195-mediated mechanism, nor does it demonstrate whether miR-195 levels predict long-term complications. The findings are correlative and require functional validation in relevant disease models.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →